Advertisement

Topics

Merck Receives Positive CHMP Opinion for PREVYMIS™ (letermovir) in the European Union

08:00 EST 13 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommend...

Other Sources for this Article

Merck
Media:
Pamela Eisele, 267-305-3558
or
Robert Consalvo, 908-740-6518
or
Investor:
Teri Loxam, 908-740-1986
or
Amy Klug, 908-740-1898

NEXT ARTICLE

More From BioPortfolio on "Merck Receives Positive CHMP Opinion for PREVYMIS™ (letermovir) in the European Union"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Transplantation
Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...